Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Current Value
$1.861 Year Return
Current Value
$1.861 Year Return
Market Cap
$134.09M
P/E Ratio
-1.81
1Y Stock Return
-34.04%
1Y Revenue Growth
76.24%
Dividend Yield
0.00%
Price to Book
1.4
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PAYC | -70.27% | $12.69B | +27.90% | 0.66% |
UNM | -54.77% | $13.77B | +76.53% | 2.07% |
FDP | -42.85% | $1.61B | +44.02% | 2.97% |
ASTE | -42.75% | $843.89M | +16.49% | 1.40% |
TRMB | -36.71% | $17.44B | +63.53% | 0.00% |
EL | -33.81% | $23.99B | -45.49% | 3.95% |
MTCH | -33.61% | $7.91B | -1.78% | 0.00% |
JBSS | -33.28% | $959.03M | -10.37% | 1.03% |
MTZ | -30.16% | $11.26B | +147.75% | 0.00% |
CNDT | -27.58% | $582.00M | +20.53% | 0.00% |
BGFV | -26.68% | $37.23M | -70.82% | 13.47% |
EXTR | -26.36% | $2.07B | -4.40% | 0.00% |
DD | -22.76% | $34.59B | +16.04% | 1.81% |
ADP | -21.09% | $124.10B | +31.76% | 1.84% |
VSTS | -20.99% | $2.05B | -6.47% | 0.90% |
BALY | -19.73% | $722.24M | +48.00% | 0.00% |
DXCM | -19.25% | $29.08B | -32.80% | 0.00% |
LUMN | -18.73% | $7.97B | +508.53% | 0.00% |
CTLT | -18.12% | $10.83B | +50.66% | 0.00% |
DIN | -17.62% | $499.02M | -27.27% | 6.25% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HLIT | <0.01% | $1.44B | +12.84% | 0.00% |
PCOR | -0.01% | $11.18B | +32.77% | 0.00% |
LTM | 0.01% | $8.37B | -100.00% | <0.01% |
VC | -0.01% | $2.50B | -23.43% | 0.00% |
ZUMZ | -0.02% | $421.11M | +19.37% | 0.00% |
ZS | -0.02% | $31.61B | +8.74% | 0.00% |
TX | -0.02% | $6.55B | -13.77% | 9.29% |
CFR | 0.02% | $8.95B | +41.44% | 2.65% |
UNIT | 0.02% | $1.44B | +9.26% | 7.55% |
ATUS | 0.03% | $1.19B | +12.61% | 0.00% |
SLP | 0.04% | $602.82M | -24.08% | 0.59% |
ENTA | 0.04% | $197.27M | +3.56% | 0.00% |
STG | 0.05% | $35.47M | +5.43% | 0.00% |
GPCR | 0.05% | $1.72B | -41.41% | 0.00% |
CGNT | -0.05% | $584.51M | +84.35% | 0.00% |
VSCO | 0.06% | $2.75B | +65.97% | 0.00% |
TXO | -0.06% | $736.85M | -2.65% | 13.08% |
WSC | -0.06% | $6.55B | -6.69% | 0.00% |
CORZ | -0.06% | $4.90B | +3,634.04% | 0.00% |
DMLP | -0.07% | $1.59B | +16.93% | 10.34% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MCY | 57.99% | $4.23B | +108.85% | 1.66% |
AIZ | 51.63% | $11.55B | +37.38% | 1.28% |
FTDR | 49.91% | $4.36B | +68.25% | 0.00% |
TT | 48.52% | $93.47B | +82.62% | 0.79% |
ALDX | 47.78% | $286.43M | +90.12% | 0.00% |
SMG | 46.97% | $4.35B | +36.09% | 3.47% |
CHEF | 45.04% | $1.73B | +65.01% | 0.00% |
TGTX | 41.40% | $5.38B | +172.69% | 0.00% |
HTZ | 33.04% | $552.14M | -53.86% | 0.00% |
ASPN | 32.97% | $1.15B | +30.72% | 0.00% |
GRMN | 32.15% | $40.15B | +73.72% | 1.41% |
BLNK | 32.12% | $153.79M | -56.45% | 0.00% |
BBDO | 31.47% | $11.53B | -17.08% | 1.69% |
PRDO | 31.21% | $1.76B | +54.49% | 1.70% |
VIV | 31.02% | $14.22B | -13.28% | 0.00% |
TRIN | 30.19% | $840.00M | -3.71% | 14.20% |
INFY | 29.04% | $91.18B | +24.91% | 2.60% |
HRZN | 28.98% | - | - | 14.29% |
OPI | 28.79% | $63.59M | -77.95% | 3.52% |
FSP | 28.55% | $201.96M | -17.72% | 2.02% |
Yahoo
(Article 223-16 of General Regulation of the French financial markets authority)PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights10/31/2024100,093,87388,569,210 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46
Yahoo
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data to enhance CAR T cell activity against solid tumors while preventing potential toxicity, will be presented at the Society for Immunotherapy of Cancer’s 39th Annual Meeting (SITC), that will take place on November 6-10, 2
SeekingAlpha
Cellectis S.A. (NASDAQ:CLLS) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ETCompany ParticipantsArthur Stril - Interim Chief Financial...
Yahoo
UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderAppointed Adrian Kilcoyne, M.D., MPH, MBA, an industry leader in the advancement of cell therapy treatment, as Chief Medical OfficerCash position of $264 million as o
Yahoo
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2024 ending September 30, 2024 on Monday, November 4, 2024 after the close of the US market. The publication will be followed by an investor conference call and webcast on Tuesday, Nov
Yahoo
Cellectis SA (CLLS) has released an update. Cellectis SA is set to present groundbreaking data on their gene-editing technologies at the ESGCT Annual Congress, showcasing advancements in TALE base editors and non-viral gene insertion methods. These developments could significantly enhance therapeutic applications, offering promising new avenues for gene therapy in hematopoietic stem and progenitor cells. Investors may find these innovations indicative of Cellectis’ potential for influencing futu
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DBA | 0.06% | $768.98M | 0.93% |
CNBS | 0.10% | $20.88M | 0.77% |
BILZ | -0.15% | $553.02M | 0.14% |
MSOS | -0.20% | $613.28M | 0.83% |
AGZD | 0.24% | $142.85M | 0.23% |
FLOT | -0.38% | $7.34B | 0.15% |
YOLO | -0.42% | $34.03M | 1.03% |
CLOU | 0.45% | $351.59M | 0.68% |
TBIL | -0.65% | $4.39B | 0.15% |
FMF | -0.70% | $243.44M | 0.95% |
GBIL | 0.77% | $5.64B | 0.12% |
SEIX | 0.86% | $267.58M | 0.62% |
EIDO | 0.94% | $302.30M | 0.59% |
XLP | 1.00% | $16.04B | 0.09% |
VDC | 1.08% | $7.06B | 0.1% |
BUXX | -1.19% | $166.76M | 0.25% |
IHF | -1.20% | $709.92M | 0.4% |
IYK | 1.30% | $1.31B | 0.4% |
HYZD | -1.40% | $161.68M | 0.43% |
FSTA | 1.41% | $1.20B | 0.084% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IDRV | 40.14% | $173.57M | 0.47% |
YYY | 38.82% | $543.26M | 4.6% |
IDV | 38.05% | $4.10B | 0.49% |
FINX | 37.85% | $338.80M | 0.68% |
BATT | 37.70% | $72.77M | 0.59% |
RLY | 37.52% | $514.96M | 0.5% |
DRIV | 37.52% | $417.18M | 0.68% |
SPEU | 37.40% | $520.52M | 0.07% |
IEUR | 37.29% | $4.18B | 0.11% |
FDD | 37.28% | $148.49M | 0.59% |
GCOW | 37.17% | $2.00B | 0.6% |
IEFA | 37.10% | $118.76B | 0.07% |
IEV | 37.06% | $1.61B | 0.61% |
DWM | 36.92% | $510.61M | 0.48% |
EWA | 36.86% | $1.47B | 0.5% |
BBAX | 36.80% | $4.72B | 0.19% |
EPP | 36.71% | $2.03B | 0.48% |
DTH | 36.59% | $314.54M | 0.58% |
EFV | 36.49% | $18.93B | 0.34% |
KOMP | 36.46% | $2.11B | 0.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -35.80% | $379.51M | 1.43% |
USDU | -22.54% | $201.83M | 0.5% |
UUP | -20.61% | $359.07M | 0.77% |
VIXY | -20.30% | $195.31M | 0.85% |
TAIL | -12.25% | $68.06M | 0.59% |
CTA | -9.66% | $359.48M | 0.78% |
WEAT | -8.16% | $123.26M | 0.28% |
CORN | -7.85% | $61.32M | 0.2% |
JBBB | -7.77% | $1.27B | 0.49% |
CLOI | -7.66% | $720.91M | 0.4% |
DBMF | -7.08% | $1.02B | 0.85% |
BOXX | -6.74% | $4.43B | 0.1949% |
CGSM | -6.69% | $519.62M | 0.25% |
SGOV | -6.60% | $27.69B | 0.09% |
FLTR | -6.58% | $1.79B | 0.14% |
EQLS | -6.31% | $8.88M | 1% |
KMLM | -5.26% | $348.59M | 0.9% |
MINT | -4.92% | $11.62B | 0.35% |
XBIL | -4.90% | $637.84M | 0.15% |
SHYD | -2.80% | $311.61M | 0.35% |